EXS	Publish
DIS	or
NIL	Perish
NIL	OXFORD
AND	–
DIS	A
IST	few
CON	years
AND	ago
NIL	,
QUC	two
GPO	Norwegian
CON	researchers
EPS	presented
HAS	their
CON	version
AND	of
DIS	a
CON	scientific-research
CON	slippery
CON	slope
NIL	,
REL	with
IST	honest
CON	errors
SUB	(
EXS	mistaken
CON	observations
AND	and
CON	analyses
NIL	)
REL	at
DEF	the
CON	top
AND	and
IST	intentional
CON	fraud
SUB	(
CON	plagiarism
EQU	,
CON	falsification
NIL	,
AND	and
CON	fabrication
NIL	)
REL	at
DEF	the
CON	bottom
NIL	.
PRO	They
EPS	placed
DEF	“
CON	publication
CON	bias
NIL	”
AND	about
AND	halfway
IST	down
DEF	the
CON	scale
NIL	–
BUT	but
PRO	it
NEC	should
EXT	have
PFT	been
QUC	much
COM	lower
NIL	.
AND	Indeed
NIL	,
CON	failure
SUB	to
EXS	publish
CON	research
CON	results
NOW	is
REL	by
AND	far
DEF	the
INT	most
IST	common
AND	and
IST	worrying
CON	form
AND	of
IST	scientific
AND	and
IST	ethical
CON	misconduct
REL	in
CON	health
CON	research
NIL	–
COO	and
PRO	it
NOW	has
EXS	had
IST	lethal
CON	consequences
NIL	.
IST	Anecdotal
CON	evidence
AND	of
CON	publication
CON	bias
NOW	has
EXS	existed
REL	for
DIS	a
IST	long
CON	time
NIL	.
AND	But
NIL	,
AND	as
CON	requirements
REL	for
EXS	registering
IST	clinical
CON	trials
NOW	have
EXS	become
MOR	more
MOR	stringent
NIL	,
HAS	its
CON	magnitude
NOW	has
EXS	become
IST	quantifiable
AND	:
DEF	the
CON	results
AND	of
REL	at
EXS	least
CON	half
AND	of
DEF	the
IST	clinical
CON	trials
AND	involving
CON	patients
AND	and
IST	healthy
CON	volunteers
NOW	remain
IST	unpublished
CON	years
REL	after
CON	completion
NIL	.
ORG	Studies
REL	with
DEF	“
IST	negative
CON	”
CON	results
NOW	are
INT	particularly
IST	unlikely
SUB	to
EXS	see
DEF	the
CON	light
AND	of
CON	day
NIL	.
AND	But
EXS	neglecting
SUB	to
CON	report
CON	research
POS	can
EXS	lead
REL	to
IST	distorted
CON	clinical-practice
CON	recommendations
EQU	,
CON	suffering
NIL	,
AND	and
CON	death
NIL	.
REL	For
CON	example
EQU	,
IST	anti-arrhythmic
CON	drugs
PST	were
EXS	prescribed
IST	widely
CON	–
REL	with
DEF	the
ORG	United States
ORG	Food
AND	and
ORG	Drug
ORG	Administration
REL	’s
CON	approval
NIL	–
SUB	to
IST	heart-attack
CON	victims
REL	for
MOR	more
MOR	than
DIS	a
CON	decade
NIL	,
REL	under
DEF	the
CON	assumption
SUB	that
EXS	reducing
CON	heart-rhythm
CON	abnormalities
FUT	would
EXS	decrease
REL	mortality
CON	rates
NIL	.
AND	But
NIL	,
AND	as
DEF	the
IST	investigative
CON	journalist
PER	Thomas
PER	J.
PER	Moore
EPS	reported
REL	in
HAS	his
CON	book
AND	Deadly
ORG	Medicine
NIL	,
REL	at
DEF	the
CON	peak
AND	of
HAS	their
CON	use
NIL	,
PRX	these
CON	drugs
PST	were
EXS	killing
IST	more
GPE	Americans
AND	each
CON	year
AND	than
PST	were
EXS	killed
AND	during
DEF	the
IST	entire
CON	Vietnam War
NIL	.
EXS	Following
PRX	this
CON	revelation
NIL	,
DIS	a
GPO	British
CON	research
CON	team
EPS	reported
DIS	a
IST	clinical
CON	trial
SUB	that
PRO	they
PST	had
EXS	carried
IST	out
MOR	more
MOR	than
DIS	a
CON	decade
AND	earlier
NIL	.
HAS	Their
CON	study
PST	had
EXS	found
DIS	a
MOR	higher
CON	death
CON	rate
AND	among
CON	patients
EXS	receiving
DIS	a
IST	new
IST	anti-arrhythmic
CON	drug
AND	than
AND	among
DST	those
EXS	receiving
DIS	a
AND	placebo.
PRO	They
PST	had
NOT	not
EXS	published
DEF	the
CON	results
NIL	,
PRO	they
EPS	explained
NIL	,
SUB	because
DEF	the
CON	drug
AND	’s
CON	development
PST	had
PFT	been
EXS	abandoned
REL	for
IST	commercial
CON	reasons
NIL	.
REL	In
CON	retrospect
NIL	,
IST	however
NIL	,
PRO	they
EPS	observed
SUB	that
HAS	their
CON	results
NIL	“
POS	might
EXT	have
EXS	provided
IST	early
CON	warning
AND	of
CON	trouble
AND	ahead
NIL	.
NIL	”
AND	Beyond
IST	avoidable
CON	suffering
AND	and
CON	death
NIL	,
CON	failure
REL	to
CON	report
CON	research
ALT	also
ENS	slows
DEF	the
CON	pace
AND	of
IST	scientific
CON	discovery
NIL	.
PRO	It
NOW	is
IST	widely
EPS	acknowledged
SUB	that
DEF	the
IST	high
IST	current
CON	level
AND	of
CON	investment
REL	in
IST	pharmaceutical
CON	research
NOW	is
IST	yielding
INT	too
IST	few
IST	substantive
CON	discoveries
NIL	.
REL	At
DIS	a
CON	meeting
REL	on
DEF	“
IST	translational
CON	research
NIL	,
NIL	”
DIS	a
IST	senior
CON	member
AND	of
DIS	a
CON	contract-research
CON	organization
AND	–
DIS	a
CON	company
AND	that
NOW	provides
IST	outsourced
CON	research
CON	services
REL	to
DEF	the
CON	pharmaceutical
AND	and
CON	biotechnology
CON	industries
NIL	–
EXS	articulated
DEF	the
CON	problem
NIL	.
NIL	“
QUE	What
IST	really
NOW	frustrates
PRO	us
NIL	,
NIL	”
PRO	he
EPS	commented
NIL	,
NIL	“
NOW	is
SUB	to
EXS	be
EXS	commissioned
REL	by
DIS	a
IST	pharmaceutical
CON	company
SUB	to
EXS	design
DIS	an
CON	early-phase
CON	trial
SUB	when
PRO	we
NOW	know
IST	already
SUB	that
PRO	it
NOW	is
EXG	going
IST	up
DIS	a
IST	blind
CON	alley
NIL	.
AND	And
DEF	the
CON	reason
PRO	we
ENS	know
SUB	that
NOW	is
SUB	that
PRO	we
NOW	’ve
PFT	been
IST	up
DEF	the
IST	blind
CON	alley
REL	with
ALT	another
CON	company
NIL	;
COO	but
SUB	that
CON	experience
NOW	remains
EXS	unreported
REL	for
IST	commercial
CON	reasons
NIL	.
NIL	”
REL	In
ALT	other
CON	words
NIL	,
DEF	the
REL	drug-discovery
CON	process
ENS	suffers
REL	from
AND	built-in
CON	inefficiency
NIL	,
EXS	owing
REL	to
IST	inadequate
CON	reporting
NIL	.
